C. Rodriguez

发表

Management of Salivary Gland Malignancy: ASCO Guideline

Nofisat Ismaila, R. Seethala, C. Glastonbury, 2021, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

NCCN Guidelines ® Insights Head and Neck Cancers , Version 2 . 2017 Featured Updates to the NCCN Guidelines

Bharat B. Mittal, Jill Gilbert, Loren K. Mell, 2017 .

Head and Neck Cancers, Version 1.2015.

J. Shah, R. Weber, A. Jimeno, 2015, Journal of the National Comprehensive Cancer Network : JNCCN.

Head and Neck Cancers, Version 2.2020, NCCN Clinical Practice Guidelines in Oncology.

Yoshimi Anzai, Thomas Galloway, Sue S Yom, 2020, Journal of the National Comprehensive Cancer Network : JNCCN.

Head and Neck Cancers, Version 2.2014

Renato Martins, Bharat B. Mittal, Jill Gilbert, 2014 .

Performance status (PS) as a predictor of poor response to immune checkpoint inhibitors (ICI) in recurrent/metastatic head and neck cancer (RMHNSCC) patients

N. Futran, G. Laramore, J. Liao, 2022, Cancer medicine.

Persistent Dysphagia After Induction Chemotherapy in Patients with Esophageal Adenocarcinoma Predicts Poor Post-Operative Outcomes

S. Murthy, L. Rybicki, G. Videtic, 2017, Journal of Gastrointestinal Cancer.

The relationship between pathologic nodal disease and residual tumor viability after induction chemotherapy in patients with locally advanced esophageal adenocarcinoma receiving a tri-modality regimen.

S. Murthy, L. Rybicki, G. Videtic, 2016, Journal of gastrointestinal oncology.

A Phase II Trial of Induction Epirubicin, Oxaliplatin, and Fluorouracil, Followed by Surgery and Postoperative Concurrent Cisplatin and Fluorouracil Chemoradiotherapy in Patients with Locoregionally Advanced Adenocarcinoma of the Esophagus and Gastroesophageal Junction

T. Rice, S. Murthy, L. Rybicki, 2014, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Postoperative Combined Modality Treatment in High Risk Resected Locally Advanced Squamous Cell Carcinomas of the Head and Neck (HNSCC)

C. Rodriguez, K. Kirtane, 2018, Front. Oncol..

The mutational landscape of recurrent versus nonrecurrent human papillomavirus-related oropharyngeal cancer.

C. Carlson, E. Mendez, Chu Chen, 2018, JCI insight.

Randomized phase III study of 2 cisplatin‐based chemoradiation regimens in locally advanced head and neck squamous cell carcinoma: Impact of changing disease epidemiology on contemporary trial design

B. Burkey, L. Rybicki, S. Koyfman, 2015, Head & neck.

Head and neck cancers, Version 2.2014. Clinical practice guidelines in oncology.

J. Shah, R. Weber, A. Jimeno, 2014, Journal of the National Comprehensive Cancer Network : JNCCN.

Survival trends in head and neck cancer: opportunities for improving outcomes.

D. Adelstein, C. Rodriguez, 2010, The oncologist.

Treatment implications of the new lung cancer staging system

C. Rodriguez, 2012, Cleveland Clinic Journal of Medicine.

Human Papillomavirus: Changing Paradigms in Oropharyngeal Cancer

D. Adelstein, C. Rodriguez, David J. Adelstein, 2010, Current oncology reports.

A Phase II study of nab-Paclitaxel (nab-P) in patients with advanced non-small cell lung cancer with EGFR mutations after frontline tyrosine kinase inhibitor therapy.

C. Baik, K. Eaton, Rebecca L. Wood, 2021, Cancer treatment and research communications.

A Phase II Study of Perioperative Concurrent Chemotherapy, Gefitinib, and Hyperfractionated Radiation Followed by Maintenance Gefitinib in Locoregionally Advanced Esophagus and Gastroesophageal Junction Cancer

T. Rice, S. Murthy, L. Rybicki, 2010, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Intended single-modality management of T1 and T2 tonsillar carcinomas: retrospective comparison of radical tonsillectomy vs radiation from a single institution.

R. Seth, R. Esclamado, J. Saxton, 2012, American journal of otolaryngology.

A Phase I/Ib Trial of the VEGFR-Sparing Multikinase RET Inhibitor RXDX-105.

A. Drilon, M. Ahn, A. Wozniak, 2018, Cancer discovery.

Randomized phase II trial of pemetrexed/cisplatin with or without CBP501 in patients with advanced malignant pleural mesothelioma.

A. Wozniak, L. Krug, J. Bauman, 2014, Lung cancer.

Oncologic outcomes of salvage surgery and immune checkpoint inhibitor therapy in recurrent head and neck squamous cell carcinoma: A single‐institution retrospective study

N. Futran, C. Rodriguez, B. Barber, 2022, Head & neck.

Concurrent cetuximab and postoperative radiation in resected high‐risk squamous cell carcinomas of the head and neck: A single‐institution experience

N. Futran, E. Mendez, G. Laramore, 2016, Head & neck.

Immunotherapy for Head and Neck Cancer in the Era of Exponentially Increasing Health Care Expenditure

C. Rodriguez, R. Santana-Davila, 2017, The oncologist.

Current and emerging standards of concomitant chemoradiotherapy.

D. Adelstein, C. Rodriguez, 2008, Seminars in oncology.

Esophagectomy for clinical high-grade dysplasia.

E. Blackstone, T. Rice, S. Murthy, 2011, European journal of cardio-thoracic surgery : official journal of the European Association for Cardio-thoracic Surgery.

Neutron Therapy for High‐Grade Salivary Carcinomas in the Adjuvant and Primary Treatment Setting

N. Futran, G. Laramore, J. Liao, 2020, The Laryngoscope.

Phase II trial of eribulin mesylate in recurrent or metastatic salivary gland malignancies

L. Chow, C. Baik, K. Eaton, 2018, Head & neck.

Neutrophil to lymphocyte ratio and peripheral blood biomarkers correlate with survival outcomes but not response among head and neck and salivary cancer treated with pembrolizumab and vorinostat

G. Laramore, J. Liao, U. Parvathaneni, 2022, Head & neck.

Single‐arm phase II study of multiagent concurrent chemoradiotherapy and gefitinib in locoregionally advanced squamous cell carcinoma of the head and neck

L. Rybicki, J. Saxton, D. Adelstein, 2012, Head & neck.

NCCN Guidelines® Insights: Head and Neck Cancers, Version 1.2022.

J. Shah, G. Weinstein, R. Weber, 2022, Journal of the National Comprehensive Cancer Network : JNCCN.

NCCN Guidelines ® Insights Head and Neck Cancers , Version 1 . 2018 Featured Updates to the NCCN Guidelines

R. Weber, A. Jimeno, M. Witek, 2018 .

Increased C-kit intensity is a poor prognostic factor for progression-free and overall survival in patients with newly diagnosed AML.

A. Advani, M. Sekeres, Barbara Tripp, 2008, Leukemia research.

A Phase II Trial of Pembrolizumab and Vorinostat in Recurrent Metastatic Head and Neck Squamous Cell Carcinomas and Salivary Gland Cancer

L. Chow, C. Baik, K. Eaton, 2019, Clinical Cancer Research.

Salivary Gland Malignancies.

E. Mendez, U. Parvathaneni, R. Martins, 2015, Hematology/oncology clinics of North America.

What is new in the management of salivary gland cancers?

D. Adelstein, C. Rodriguez, 2011, Current opinion in oncology.

A phase II trial of gefitinib for recurrent or metastatic cancer of the esophagus or gastroesophageal junction

T. Rice, L. Rybicki, D. Adelstein, 2012, Investigational New Drugs.

Pembrolizumab versus methotrexate, docetaxel, or cetuximab for recurrent or metastatic head-and-neck squamous cell carcinoma (KEYNOTE-040): a randomised, open-label, phase 3 study

O. V. Matorin, Kelvin K. W. Chan, Sung-Bae Kim, 2019, The Lancet.

FOXM1 drives HPV+ HNSCC sensitivity to WEE1 inhibition

B. Clurman, E. Mendez, K. Loeb, 2020, Proceedings of the National Academy of Sciences.

A Phase I Clinical Trial of AZD1775 in Combination with Neoadjuvant Weekly Docetaxel and Cisplatin before Definitive Therapy in Head and Neck Squamous Cell Carcinoma

N. Futran, E. Mendez, L. Chow, 2018, Clinical Cancer Research.

A phase I/II trial of concurrent immunotherapy with chemoradiation in locally advanced larynx cancer

V. Takiar, T. Wise-Draper, K. Redmond, 2022, Laryngoscope investigative otolaryngology.

Management of the Neck in Squamous Cell Carcinoma of the Oral Cavity and Oropharynx: ASCO Clinical Practice Guideline.

Nofisat Ismaila, E. Sturgis, S. Yom, 2019, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Genomic medicine and targeted therapy for solid tumors

Emily A. Stevens, C. Rodriguez, Cristina P Rodriguez, 2015, Journal of surgical oncology.

Clinicopathologic features and treatment outcomes of patients with human epidermal growth factor receptor 2-positive adenocarcinoma of the esophagus and gastroesophageal junction.

T. Rice, R. Tubbs, L. Rybicki, 2013, Diseases of the esophagus : official journal of the International Society for Diseases of the Esophagus.

Fatal cerebral air embolus complicating multimodality treatment of esophageal cancer.

T. Rice, S. Murthy, E. Manno, 2011, The Annals of thoracic surgery.

Diagnosis and Management of Squamous Cell Carcinoma of Unknown Primary in the Head and Neck: ASCO Guideline.

Nofisat Ismaila, J. Waldron, M. Witek, 2020, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Principles of Systemic Chemotherapy for Squamous Cell Head and Neck Cancer

D. Adelstein, C. Rodriguez, 2011 .

Clinical predictors of larynx preservation after multiagent concurrent chemoradiotherapy

L. Rybicki, M. Strome, R. Esclamado, 2008, Head & neck.

Multi‐agent concurrent chemoradiotherapy for locally advanced head and neck squamous cell cancer in the elderly

J. Saxton, D. Adelstein, C. Rodriguez, 2012, Head & neck.

Impact of remission induction chemotherapy on survival in older adults with acute myeloid leukemia

A. Advani, M. Sekeres, M. Kalaycio, 2007, Cancer.

Predictors of outcome with cetuximab and paclitaxel for head and neck squamous cell carcinoma

L. Chow, C. Baik, K. Eaton, 2017, The Laryngoscope.

Risk of recurrence in patients with surgically resected stage I non-small cell lung carcinoma: histopathologic and immunohistochemical analysis.

M. Vázquez, C. Rodriguez, C. Poleri, 2003, Chest.

Racial disparity in oncologic and quality‐of‐life outcomes in patients with locally advanced head and neck squamous cell carcinomas enrolled in a randomized phase 2 trial

L. Chow, M. Guerriero, C. Baik, 2018, Cancer.

Wound Complications in Head and Neck Squamous Cell Carcinomas After Anti–PD‐1 Therapy

N. Futran, E. Mendez, L. Chow, 2019, The Laryngoscope.

Treatment of Tonsillar Carcinoma following Nononcologic Tonsillectomy: Efficacy of Transoral Robotic Revision Tonsillectomy

N. Futran, Sapna Patel, C. Rodriguez, 2018, Otolaryngology--head and neck surgery : official journal of American Academy of Otolaryngology-Head and Neck Surgery.

A phase III randomized trial of two cisplatin-based concurrent chemoradiation (CCRT) regimens for locally advanced head and neck squamous cell carcinoma (LAHNSCC).

B. Burkey, L. Rybicki, S. Koyfman, 2013 .

Impact of socioeconomic status and distance from treatment center on survival in patients receiving remission induction therapy for newly diagnosed acute myeloid leukemia.

A. Advani, L. Rybicki, M. Sekeres, 2008, Leukemia research.

Phase I/II trial of pembrolizumab(P) and vorinostat(V) in recurrent metastatic head and neck squamous cell carcinomas (HN) and salivary gland cancer (SGC).

L. Chow, V. Wu, C. Baik, 2018 .

Peripheral lymphocytes and lactate dehydrogenase correlate with response and survival in head and neck cancers treated with immune checkpoint inhibitors

J. Liao, U. Parvathaneni, R. Martins, 2023, Cancer medicine.

Mature Results from a Phase II Trial of Postoperative Concurrent Chemoradiotherapy for Poor Prognosis Cancer of the Esophagus and Gastroesophageal Junction

T. Rice, S. Murthy, L. Rybicki, 2009, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Gefitinib in definitive management of esophageal or gastroesophageal junction cancer: a retrospective analysis of two clinical trials.

T. Rice, S. Murthy, R. Tubbs, 2015, Diseases of the esophagus : official journal of the International Society for Diseases of the Esophagus.

919MO ACCURACY a phase II trial of AL101, a selective gamma secretase inhibitor, in subjects with recurrent/metastatic (R/M) adenoid cystic carcinoma (ACC) harboring Notch activating mutations (Notchmut)

C. Perez, S. Hotte, E. Winquist, 2020 .

Radiation therapy for low- and high-risk perineural invasion in head and neck cutaneous squamous cell carcinoma: Clinical outcomes and patterns of failure.

K. Wallner, N. Futran, J. Liao, 2023, Head & neck.

Comparison of Prognostic Factors and Outcomes of Patients with Secondary Acute Myeloid Leukemia (AML) Following Myelodysplastic Syndromes (MDS), Myeloproliferative Disorders (MPD), or Therapy-Related AML (t-AML).

J. Maciejewski, A. Advani, M. Sekeres, 2007 .

NCCN Guidelines Insights: Head and Neck Cancers, Version 2.2017.

J. Shah, R. Weber, A. Jimeno, 2017, Journal of the National Comprehensive Cancer Network : JNCCN.

NCCN Guidelines Insights: Head and Neck Cancers, Version 1.2018.

R. Weber, A. Jimeno, M. Witek, 2018, Journal of the National Comprehensive Cancer Network : JNCCN.

Pembrolizumab versus methotrexate, docetaxel, or cetuximab for recurrent or metastatic head-and-neck squamous cell carcinoma (KEYNOTE-040): a randomised, open-label, phase 3 study

O. V. Matorin, Kelvin K. W. Chan, Sung-Bae Kim, 2019, The Lancet.

Multiagent concurrent chemoradiotherapy (MACCRT) and gefitinib in locoregionally advanced head and neck squamous cell cancer (HNSCC).

L. Rybicki, J. Saxton, D. Adelstein, 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

LBA19A phase 1b study of RXDX-105, a VEGFR-sparing potent RET inhibitor, in RETi-naïve patients with RET fusion-positive NSCLC

A. Drilon, M. Ahn, R. Doebele, 2017 .